FIG Invests in Elitepharm to Integrate AI in Nutraceuticals

February 17, 2025
Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, aiming to enhance dietary supplement production with AI technology.

Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, as stated in a press release. This move positions FIG as a major shareholder in Elitepharm, a leading French company specializing in the formulation and production of dietary supplements.

The investment aims to leverage AI technology to improve the efficiency and effectiveness of dietary supplement production. Narek Sirakanyan, President and CEO of FIG, highlighted the strategic importance of this investment, noting that France's regulatory environment and technological advancements make it an ideal location for producing dietary supplements.

Elitepharm plans to use this investment to accelerate its commercial and industrial development. The company intends to strengthen its existing facilities, acquire new production sites, and expand its private label portfolio. This expansion is part of a broader strategy to enhance control over the value chain and ensure high-quality production standards.

The partnership between FIG and Elitepharm is based on a shared vision of innovation and industrial excellence, with the goal of establishing Elitepharm as a major player in the European market by 2029.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/07
Anthropic Pushes IPO Marketing to Mid October
09/06
XDOF Nears Series B at $1.2 Billion Valuation
09/05
BUUU Group Agrees to Acquire 60% of Brightray Science
09/05
CollPlant Acquires LightSolver and Enters Photonic Computing
09/04
Guardio Raises $40 Million at $1.1 Billion Valuation

More from: Life Sciences

09/07
Rentosertib Study Finds Lower Predicted Biological Age in IPF Trial
09/07
Sky Labs Presents CART Blood Pressure Studies at ESC 2026
09/05
HoneyNaps Develops Wireless Sleep Monitoring System With Four Skin Patches
09/05
Carestream Updates DRX LC Detector With AI Noise Reduction
09/05
EClinCloud AI Platform Supports More Than 1,100 Clinical Trials

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You May Also Like